1. Home
  2. MCR vs ACIU Comparison

MCR vs ACIU Comparison

Compare MCR & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MFS Charter Income Trust

MCR

MFS Charter Income Trust

HOLD

Current Price

$6.26

Market Cap

262.2M

Sector

Finance

ML Signal

HOLD

Logo AC Immune SA

ACIU

AC Immune SA

HOLD

Current Price

$2.52

Market Cap

213.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MCR
ACIU
Founded
1989
2003
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
262.2M
213.3M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
MCR
ACIU
Price
$6.26
$2.52
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
79.2K
291.7K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
8.52%
N/A
EPS Growth
N/A
N/A
EPS
0.38
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$495.67
P/E Ratio
$16.47
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.57
$1.43
52 Week High
$6.57
$4.00

Technical Indicators

Market Signals
Indicator
MCR
ACIU
Relative Strength Index (RSI) 53.93 30.50
Support Level $6.25 $2.45
Resistance Level $6.34 $3.19
Average True Range (ATR) 0.04 0.18
MACD 0.00 -0.07
Stochastic Oscillator 62.97 7.29

Price Performance

Historical Comparison
MCR
ACIU

About MCR MFS Charter Income Trust

MFS Charter Income Trust is a United States-based closed-end fund. Its investment objective is to seek high current income, but may also consider capital appreciation. The fund invests the assets in Debt Instruments, Corporate Bonds, U.S. Government Securities, Foreign Government Securities, Securitized Instruments, Derivatives, Principal Risks, Debt Management Risk, Investment Selection Risk, Interest Rate Risk, Credit Risk, Foreign Risks, Emerging Markets Risk, Currency Risk, Leveraging Risk, Operational and Cybersecurity Risk, Active and Frequent Trading, and etc of different market countries.

About ACIU AC Immune SA

AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Share on Social Networks: